Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8) an open-label randomised controlled phase 3 trial /

Soria Jean-Charles, Felip Enriqueta, Cobo Manuel, Lu Shun, Syrigos Konstantinos, Lee Ki Hyeong, Goeker Erdem, Georgoulias Vassilis, Li Wei, Isla Dolores, Guclu Salih Z, Morabito Alessandro, Min Young J, Ardizzoni Andrea, Gadgeel Shirish M, Wang Bushi, Chand Vikram K, Goss Glenwood D, Kollaborációs szervezet: LUX-Lung 8 Investigators, Somfay Attila, et al
2015